Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC.INO · Entity 6589 | Director · Chief Executive Officer | March 11, 2022 | March 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INOVIO PHARMACEUTICALS, INC.
Report date March 11, 2022 · Filed March 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,422,627 |
Ending reported balance
After 2022-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-11 · Exercise / conversion · Acquired 139,387 · Balance 1,462,325 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. Row 2 · 2022-03-11 · Tax withholding · Disposed 39,698 · Balance 1,422,627 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 139,386 |
Reported balance
After 2022-03-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-03-11 · Exercise / conversion · Disposed 139,387 · Balance 139,386 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Limited Partnership | 816,527 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 816,527 |
| Common StockSEC Table I · non-derivative | IndirectBy Daughter: EK | 33,563 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 33,563 |
| Common StockSEC Table I · non-derivative | IndirectBy Son: JK1 | 33,775 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 33,775 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 5,975 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,975 |
| Common StockSEC Table I · non-derivative | IndirectBy Son: JK2 | 33,533 |
Reported balance
Holding disclosure · report date 2022-03-11 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 33,533 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 418,160 restricted stock units is as follows: 139,387 shares vested on March 11, 2021; 139,387 shares vested on March 11, 2022; 139,386 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2017 Filed Mar 7, 2017 21:41 UTC | INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 | Exercise / conversionCommon Stock | 13,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001055726-17-000002 · wf-form4_148892288607267.xml · nonDerivative · entry 1 Kim Jong Joseph · CIK 0001464549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,968,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 40,000 restricted stock units is as follows: 13,334 shares vested on March 5, 2016; 13,333 shares vested on March 5, 2017; 13,333 shares will vest on March 5, 2018. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.